These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35143051)

  • 41. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer, unproven therapies, and magic.
    Wein S
    Oncology (Williston Park); 2000 Sep; 14(9):1345-50; discussion 1355-9. PubMed ID: 11033831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory issues in cellular therapies.
    Gee AP
    J Cell Biochem Suppl; 2002; 38():104-12. PubMed ID: 12046844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future.
    Pimenta C; Bettiol V; Alencar-Silva T; Franco OL; Pogue R; Carvalho JL; Felipe MSS
    Clin Ther; 2021 May; 43(5):e103-e138. PubMed ID: 33892966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory Framework for Academic Investigator-Sponsored Investigational New Drug Development of Cell and Gene Therapies in the USA.
    Dasgupta A; Herzegh K; Spencer HT; Doering C; Day E; Swaney WP
    Curr Stem Cell Rep; 2021; 7(4):129-139. PubMed ID: 34608428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.
    Heslop JA; Hammond TG; Santeramo I; Tort Piella A; Hopp I; Zhou J; Baty R; Graziano EI; Proto Marco B; Caron A; Sköld P; Andrews PW; Baxter MA; Hay DC; Hamdam J; Sharpe ME; Patel S; Jones DR; Reinhardt J; Danen EH; Ben-David U; Stacey G; Björquist P; Piner J; Mills J; Rowe C; Pellegrini G; Sethu S; Antoine DJ; Cross MJ; Murray P; Williams DP; Kitteringham NR; Goldring CE; Park BK
    Stem Cells Transl Med; 2015 Apr; 4(4):389-400. PubMed ID: 25722427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
    Bonomi P; Stuccio N; Delgra CJ; Chuk MK; Spira A; Deitz AC; Blumenthal GM; Ferris A; Gong Y; He J; Basu Roy U; Selig W
    Ther Innov Regul Sci; 2020 Sep; 54(5):1208-1214. PubMed ID: 32865803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Professional regulation: a potentially valuable tool in responding to "stem cell tourism".
    Zarzeczny A; Caulfield T; Ogbogu U; Bell P; Crooks VA; Kamenova K; Master Z; Rachul C; Snyder J; Toews M; Zoeller S
    Stem Cell Reports; 2014 Sep; 3(3):379-84. PubMed ID: 25241736
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Promoting the ethical use of safe and effective cell-based products: the Andalusian plan on regenerative medicine.
    Cuende N; Álvarez-Márquez AJ; Díaz-Aunión C; Castro P; Huet J; Pérez-Villares JM
    Cytotherapy; 2020 Dec; 22(12):712-717. PubMed ID: 32878735
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unproven methods in cancer treatment.
    Hauser SP
    Curr Opin Oncol; 1993 Jul; 5(4):646-54. PubMed ID: 8364081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Representations of stem cell clinics on Twitter.
    Kamenova K; Reshef A; Caulfield T
    Stem Cell Rev Rep; 2014 Dec; 10(6):753-60. PubMed ID: 24970380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference.
    Chu CR; Rodeo S; Bhutani N; Goodrich LR; Huard J; Irrgang J; LaPrade RF; Lattermann C; Lu Y; Mandelbaum B; Mao J; McIntyre L; Mishra A; Muschler GF; Piuzzi NS; Potter H; Spindler K; Tokish JM; Tuan R; Zaslav K; Maloney W
    J Am Acad Orthop Surg; 2019 Jan; 27(2):e50-e63. PubMed ID: 30300216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ethical, scientific, and educational concerns with unproven medications.
    Pray WS
    Am J Pharm Educ; 2006 Dec; 70(6):141. PubMed ID: 17332867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions?
    Chapman CR; Caplan AL
    AMA J Ethics; 2019 Dec; 21(12):E1021-1028. PubMed ID: 31876464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better?
    Ogbogu U; Rachul C; Caulfield T
    Regen Med; 2013 May; 8(3):361-9. PubMed ID: 23627829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The current status of clinics providing private practice cell therapy in Japan.
    Fujita M; Hatta T; Ozeki R; Akabayashi A
    Regen Med; 2016 Jan; 11(1):23-32. PubMed ID: 26376631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Accelerating the development of innovative cellular therapy products for the treatment of cancer.
    Stewart MD; Keane A; Butterfield LH; Levine BL; Thompson B; Xu Y; Ramsborg C; Lee A; Kalos M; Koerner C; Moore T; Markovic I; Lasiter L; Ibrahim R; Bluestone J; Sigal E; Allen J
    Cytotherapy; 2020 May; 22(5):239-246. PubMed ID: 32199724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.